Clinical Trial Update: Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients. [Phase 3]

View source ↗

Summary

Phase 3 clinical study update for Nanogen Pegcyte in preventing CIN in breast cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pegcyte (Pegcyte)

Snippet

Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Conditions: Breast Cancer Female | Phase 3 | Status: COMPLETED